Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.

Blood - 1 Oct 2007

de Lavallade Hugues, Khorashad Jamshid S, Davis Howard P, Milojkovic Dragana, Kaeda Jaspal S, Goldman John M, Apperley Jane F, Marin David

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Fusion Proteins, bcr-abl
Share to Interferon-alpha
Share to Isoleucine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kinetics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Salvage Therapy

Share to Tyrosine

Source

Identifiers

PMID: 17881650
DOI: 10.1182/blood-2007-06-094508

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.PMID 17881650Read ↗

The effectiveness of interferon-α combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation.Semantic proximity Read ↗

BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?Semantic proximity Read ↗

Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation.Semantic proximity Read ↗

Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy.Semantic proximity Read ↗

Interferon-α Based Individualized Treatment of a High Risk Chronic Myelogenous Leukemia Patient Harboring T315I Mutation.Semantic proximity Read ↗

Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation.Semantic proximity Read ↗

[Pilot treatment for 13 BCR-ABL positive leukemia patients with T315I mutation].Semantic proximity Read ↗

Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.Semantic proximity Read ↗

Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfaSemantic proximity Read ↗

Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis.Semantic proximity Read ↗

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.